Scholarlink

<p>With the increasing importance of nuclear medicine therapy in overall cancer care and the introduction of <sup>177</sup>Lu-PSMA-617 to Japan being imminent, the Policy Recommendations for Promoting Nuclear Medicine Therapy in Japan from the Working Group for Promoting Nuclear Medicine Therapy of the Japan Society of Clinical Oncology (JSCO) aim to identify issues related to nuclear medicine therapy and propose measures to address them, in order to further advance nuclear medicine therapy in Japan. It is necessary to create an environment in which each medical institution can proactively introduce nuclear medicine therapy by taking measures that target discharge criteria, medical fees, and human resource development and link them organically. The Working Group believes that it is necessary to continue examining long-term issues taking into account the changes that have occurred since the introduction of <sup>177</sup>Lu-PSMA-617, as well as trends in nuclear medicine therapy other than <sup>177</sup>Lu-PSMA-617 that are expected to be introduced in the future. In addition, as the “Action Plans for Promoting the Production and Use of Medical Radioisotopes” have been formulated and the advancement of nuclear medicine therapy has become one of the nation’s major policy priorities, JSCO will continue to actively work with relevant ministries and local governments to resolve the various issues of nuclear medicine therapy, including the smooth introduction of <sup>177</sup>Lu-PSMA-617.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Policy recommendations for promoting nuclear medicine therapy in Japan 2025, from the Working Group for promoting nuclear medicine therapy of the Japan Society of Clinical Oncology

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年9月30日

查看全文
  • Kotaro Suzuki,
  • Hideaki Miyake,
  • Anri Inaki,
  • Shoko Takano,
  • Yasutoshi Kuboki,
  • Takashi Mizowaki,
  • Katsumasa Nakamura,
  • Makoto Ueno,
  • Shigemi Matsumoto,
  • Daisuke Obinata,
  • Tohru Nakagawa,
  • Masato Murakami,
  • Yoshiyuki Majima,
  • Megumu Yokono,
  • Masao Namba,
  • Takayuki Yoshino

摘要

With the increasing importance of nuclear medicine therapy in overall cancer care and the introduction of 177Lu-PSMA-617 to Japan being imminent, the Policy Recommendations for Promoting Nuclear Medicine Therapy in Japan from the Working Group for Promoting Nuclear Medicine Therapy of the Japan Society of Clinical Oncology (JSCO) aim to identify issues related to nuclear medicine therapy and propose measures to address them, in order to further advance nuclear medicine therapy in Japan. It is necessary to create an environment in which each medical institution can proactively introduce nuclear medicine therapy by taking measures that target discharge criteria, medical fees, and human resource development and link them organically. The Working Group believes that it is necessary to continue examining long-term issues taking into account the changes that have occurred since the introduction of 177Lu-PSMA-617, as well as trends in nuclear medicine therapy other than 177Lu-PSMA-617 that are expected to be introduced in the future. In addition, as the “Action Plans for Promoting the Production and Use of Medical Radioisotopes” have been formulated and the advancement of nuclear medicine therapy has become one of the nation’s major policy priorities, JSCO will continue to actively work with relevant ministries and local governments to resolve the various issues of nuclear medicine therapy, including the smooth introduction of 177Lu-PSMA-617.